<DOC>
	<DOCNO>NCT01664676</DOCNO>
	<brief_summary>Recent study rodents show glucagon-like peptide-1 ( GLP-1 ) analogues protect diabetic nephropathy . We hypothesise also case human . This study investigate short-term effect liraglutide ( GLP-1 analogue ) kidneys type 2 diabetic patient . Impact basic kidney physiological determine kidney injury marker measure surrogate parameter kidney protection .</brief_summary>
	<brief_title>Effects Liraglutide Kidney Function Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Male gender T2DM , diagnose accord international guideline Age 2060 year , include Body Mass Index ( BMI ) : 2032 kg/m2 , include Metformin treatment Albumin/creatinine ratio &lt; 25 mg/mmol Known suspect allergy trial product relate product Previous participation trial Previous treatment GLP1 analogues DPP4 inhibitor Current treatment antidiabetic drug metformin Poorly regulate glycemic control ( HbA1c &gt; 8 % ) Impaired kidney function : estimate GFR &lt; 70ml/min Impaired liver function : liver parameter exceed 2 time upper normal limit Subjects active malignancy Severe cardiac insufficiency classify accord NYHA IIIIV Unstable angina pectoris , acute myocardial infarction ( AMI ) within last 12 month Severe , uncontrolled hypertension : sit blood pressure ( BP ) &gt; 180/110 mmHg Antihypertensive treatment consist two different pharmaceutical product Symptoms relate benign prostate hyperplasia Claustrophobia Any metal body implant History pancreatitis , type 1 diabetes , gastroparesis multiple endocrine neoplasia syndrome type 2 Personal family history medullary thyroid carcinoma Any diseases judge investigator could affect trial Any medication judge investigator could affect trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>liraglutide</keyword>
	<keyword>victoza</keyword>
	<keyword>GLP-1</keyword>
	<keyword>kidney</keyword>
	<keyword>diabetes</keyword>
	<keyword>renal</keyword>
	<keyword>diabetic nephropathy</keyword>
</DOC>